Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest from Adam Zamecnik
The Polish player has won two grants sourced from the government’s National Recovery and Resilience Plan, which has given out $28.1m in funding in the latest round.
Having secured approvals for the Eylea biosimilar in major markets such as the US and Europe, Formycon has signed a fresh licensing deal with Lotus Pharmaceutical, giving away rights to the asset in the APAC region.
Zydus’ latest results faced scrutiny from industry analysts due to a mixed performance where weaker revenue in the Indian company’s domestic market was offset by growth in the US. Meanwhile, the firm has just agreed a deal with Synthon for a 505(b)(2) hybrid product in the US.
The commercialization of the generic version of Hospira’s THAM solution will be carried out by A.forall’s US subsidiary Milla Pharmaceuticals.
The Chinese company started the new year with a further business agreement after announcing a flurry of biosimilar partnership deals in 2024.